Latest Updates
-
Use of CRISPR-Cas9 gene editing technique to reduce Kaposi’s sarcoma-associated herpesvirus latency CRISPR-Cas9 has been used for the first time to successfully edit the latency-associated nuclear antigen (LANA) of the KSHV virus, and reduce viral episome burden in infected cells
-
Early and continuous HIV treatment offers protection against a large number of AIDS and non-AIDS related events A pooled analysis of data from SMART and START studies allows calculating the magnitude and quality of benefits of life-long antiretroviral treatment
-
FDA approves Vitrakvi for solid tumors driven by rare mutation "Site-agnostic" oral therapy for tumors with NTRK gene fusion.